APOE and Alzheimer disease: Our results are consistent with results from a rosiglitazone clinical trial in which treatment improved cognition in APOEε4 negative patients with mild to moderate AD [30] and a recently published paper that observed APOE isoform dependent effects of rosiglitazone in adipose tissue [58].